Detalhe da pesquisa
1.
Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
BMC Cancer
; 21(1): 362, 2021 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827689
2.
High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
BMC Pharmacol Toxicol
; 22(1): 63, 2021 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696815